Protocol Ledger

NCT05085028 · Phase III · RECRUITING

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Interventional Phase III clinical trial protocol NCT05085028 sponsored by Imperial College London in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-23 Enrollment: 1,750 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05085028
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,750 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05085028
Protocol FieldVerified Registry Value
NCT IdentifierNCT05085028
Consolidated Lead SponsorImperial College London
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,750 participants (ESTIMATED)
Registered Start Date2022-06-23
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI